Celecoxib-induced nonoliguric acute renal failure.
OBJECTIVE
To report a case of nonoliguric acute renal failure secondary to use of celecoxib in a patient with rheumatoid arthritis.


METHODS
A 43-year-old Hispanic woman started receiving celecoxib 200 mg/d for treatment of rheumatoid arthritis. Fourteen days after initiating therapy, she developed nonoliguric acute renal failure. Celecoxib was discontinued. Renal function improved, but had not returned to normal 30 days after presentation.


CONCLUSIONS
Only 2 cases of reversible oliguric acute renal failure and volume overload have been reported 13 and 14 days after initiating therapy with celecoxib. Renal function in the 2 patients returned to baseline after treatment with diuretics. To our knowledge, the development of nonoliguric acute renal failure secondary to treatment with celecoxib has not previously been reported.


CONCLUSIONS
Celecoxib can probably result in reversible, or nonoliguric, acute renal failure. Although renal function improves after discontinuation of celecoxib, it may not return to baseline. Celecoxib should be used cautiously in individuals at risk of developing acute renal failure.
Alkhuja
Samer
S
Division of Critical Care Medicine, Department of Medicine, St. Barnabas Hospital, Weill Medical College of Cornell University, Bronx, NY, USA. salkuja@aol.com
Menkel
Robert A
RA
Alwarshetty
Mamata
M
Ibrahimbacha
Ahmad M
AM
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000473:pathology; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology; D007677:Kidney Function Tests; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib